Company Overview and News
Realty Income Corporation continues to show solid financial strength and has room to grow its distributions to shareholders, despite pressure from e-commerce giants and rising interest rates.
I like making money in the stock market, but I love dividends. You see, the problem with capital gains is that to actually enjoy them, you have to sell your shares. The beauty of dividend stocks is that you get to enjoy the fruits of your investment without having to actually sell anything. Think of it as milking a cow rather than killing it for meat. Which sounds like the better long-term plan to you?
RNP EVV O MAIN LTC OPRF PSEC VER MSCA.CL EPR MSCA PBB STAG
The Fed already has raised interest rates twice this year, and while the broad equity market (SPY) seems to ignore these hikes, REIT investors have shown great fear in anticipation of them.
SNR O OPRF
Realty Income Corporation (O - Free Report) recently announced its 98th dividend hike since the company’s NYSE listing in 1994. The company will now pay 22.05 cents per share compared with the 22 cents paid earlier. Realty Income will pay the dividend on Oct 15 to shareholders on record as of Oct 1, 2018. The latest dividend rate marks an annualized amount of $2.646 per share versus the prior rate of $2.
UNP O UE.WI OPRF TCO UE MAC
This month's article marks the forty-second installment in my ongoing series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for "Minne(sota) 'n Monthly."
UNM VIG MSCA.CL MSCA MAIN ITW O OPRF
2018-09-15 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to O / Realty Income Corp. on message board site Silicon Investor.
as of ET